Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Shares Shorted: Short Interest Up 56.8% in September

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 2,067,445 shares, a growth of 56.8% from the September 15th total of 1,318,893 shares. Currently, 8.6% of the company’s shares are short sold. Based on an average daily volume of 569,389 shares, the days-to-cover ratio is presently 3.6 days.

Sensei Biotherapeutics Trading Down 8.7%

FTH stock traded down $1.80 during trading on Friday, reaching $18.80. 595,931 shares of the stock were exchanged, compared to its average volume of 436,135. The business’s 50 day simple moving average is $31.39. Sensei Biotherapeutics has a twelve month low of $7.45 and a twelve month high of $42.14. The firm has a market capitalization of $485.79 million, a price-to-earnings ratio of -0.13 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. As a group, sell-side analysts predict that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several institutional investors have recently modified their holdings of FTH. Citadel Advisors LLC bought a new stake in shares of Sensei Biotherapeutics during the 2nd quarter worth $307,000. Renaissance Technologies LLC grew its position in Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares during the period. Bank of America Corp DE increased its holdings in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the last quarter. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics during the first quarter worth about $4,188,000. Finally, Alyeska Investment Group L.P. bought a new stake in Sensei Biotherapeutics in the second quarter worth about $3,610,000. 10.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

FTH has been the subject of several recent analyst reports. Wall Street Zen cut Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, September 14th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. Needham & Company LLC started coverage on shares of Sensei Biotherapeutics in a research report on Friday, August 21st. They set a “buy” rating and a $56.00 price objective for the company. Finally, BTIG Research reiterated a “buy” rating and issued a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.